Dupilumbab- application for PBS listing unsuccessful
Fellows are advised that the recent application by Sanofi-Aventis for the listing of dupilumab on the Pharmaceutical Benefits Scheme) PBS has been rejected by the Pharmaceutical Benefits Advisory Committee (PBAC).
This resubmission was to request an authority required listing for the treatment of chronic, moderate to severe atopic dermatitis in patients who have had an inadequate response to topical therapies. College was approached by the PBAC for independent expert advice during the application’s assessment and support for the listing of dupilumab was provided.
The PBAC rejected the resubmission on the grounds that the treatment was not cost effective at the price proposed, however its effectiveness was acknowledged in a therapeutic area of high clinical need.
College is seeking further information and will keep members updated on this matter.